India’s obesity drug market is set for intense competition with Novo Nordisk launching Wegovy to challenge Eli Lilly’s Mounjaro, which gained early traction. Both drugs address rising obesity and diabetes rates, with Mounjaro showing significant weight loss in trials. Wegovy boasts cardiovascular benefits and a competitive pricing strategy.
Categories
Finance/Money
A big fat fight has just broken out in India
